Cite
HARVARD Citation
Santini, V. et al. (n.d.). Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS). Leukemia research. pp. S14-. [Online].